The Conversation (0)
A cancer diagnosis is a challenge in and of itself, but a lack of effective psychiatric support makes it even worse. Patients report feelings of helplessness and a hastened desire for death, and researchers are now exploring how natural psychedelic compounds can be transformed into practical mental health treatments for cancer patients. Albert Labs (CSE:ABRT) is a Vancouver-based research and drug development company presently developing a psilocybin-based medication for patients with cancer-related distress. Albert Labs has a patented process for creating the active pharmaceutical ingredient (API) used in its inaugural medication.
Company Highlights
- Albert Labs has an existing relationship with the largest oncology centre in Europe, setting the stage for rapid commercial deployment of its medication upon completion of clinical trials and receipt of regulatory approval.
- The usage of the Real-World Evidence clinical model will accelerate the clinical trials and allow the company to reach regulatory approval much faster than traditional trials.
- Albert Labs has a proprietary and provisionally patented process for producing the active ingredient in its medicines that allows improved scale and standardization.
- A diverse team of doctors, scientists, and managers are leading the company towards receiving approval for its inaugural medicine and beyond.
This Albert Labs profile is part of a paid investor education campaign.*
ABRT:CNX
